Overview

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, double-masked, parallel study.
Phase:
Phase 4
Details
Lead Sponsor:
Andover Research Eye Institute
Treatments:
Dextrans
Fluticasone
Olopatadine Hydrochloride
Ophthalmic Solutions
Xhance